Advancements in the diagnosis and treatment of thoracic cancers have improved survival rates, making survivorship issues such as fertility and sexual wellness a priority.

The management of stage III NSCLC is controversial and rapidly evolving, to the point that practitioners have difficulty processing and understanding the fast moving changes in the standard of care and communications among multidisciplinary teams is challenging given the uneven knowledge levels.

The role of multidisciplinary care for small cell lung cancer has never been more important. Novel insights into subclassification of small cell lung cancer may unlock novel therapies that may be effective for each subtype.

Thymic malignancies and mesothelioma are rare cancers that require complex multidisciplinary management.

This will be an overview session addressing the s

There are many ongoing advances in patient safety in the context of radiation therapy delivery, clinical research on treatment options, and advanced techniques in radiotherapy delivery. Failure to stay informed leads to lower quality of care by practicing clinicians.

There are phase II randomized trials that show a benefit to local consolidative SBRT in oligometastatic non-small cell lung cancer. There are pending phase III trials that have not yet read out.

Advances in medical oncology, radiation oncology and thoracic surgery have made advanced treatments available to older and more frail patients. A better understanding the interaction of patient frailty and comorbidities to evolving interventions and outcomes is needed.

Surgical outcomes are less than ideal and recent data will be reviewed on optimal combination of immunotherapy with surgery to improve those outcomes.

The session will provide updated information about former and novel regulatory approvals requiring the use of biomarkers for patient selection to optimal anti-cancer treatments.


Subscribe to RSS - OnDemand Meeting